Viromed Medical AG, a medical technology company specializing in cold plasma technology, has announced the signing of new distribution partnerships for its ViroCAP® product. These agreements cover Spain, Portugal, Greece, the Balkan region, Romania, and Saudi Arabia, marking a significant expansion of the company's international presence. Each of the six partnerships is with a separate company and pertains to an individual market, with minimum purchase quantities agreed upon. Based on these contracts, Viromed expects additional sales of at least 3,000 devices per year.
ViroCAP® is a mobile medical device designed for the treatment of skin conditions using cold atmospheric plasma. It is intended for use by hospitals, private practice physicians, and surgically active medical specialists. The device has been a key product in Viromed's portfolio, and the new partnerships are expected to boost its adoption in Southern and South-Eastern Europe as well as the Middle East.
Uwe Perbandt, Chief Executive Officer of Viromed Medical AG, commented on the development: “With these new distribution partners, we are opening up several attractive markets in Southern and South-Eastern Europe as well as in the Middle East. The strong interest shown by our distribution partners underlines the high demand for our cold plasma technology. The new distribution partnerships are another important step in the implementation of our dynamic growth phase. Partnerships for additional countries are in preparation and are expected to be signed within the next four to six weeks.”
This expansion builds on Viromed's existing international distribution network. The company already has numerous distribution and marketing partnerships in place, including an exclusive distribution agreement with the Korean company UMECO covering ten Asian countries, and a distribution partnership with TriPart TITAN GmbH & Co. KG for the Turkish market. These agreements highlight Viromed's strategy to establish a broad global footprint for its cold plasma technology.
The significance of these partnerships lies in the growing acceptance and demand for cold plasma technology in medical applications. Cold atmospheric plasma has shown promise in wound healing, skin regeneration, and antimicrobial treatments, making it a valuable tool in modern medicine. By expanding into new markets, Viromed is positioning itself to capitalize on this trend and increase its market share.
Viromed Medical AG specializes in the development, manufacture, and distribution of medical products. The company, listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications through its wholly owned subsidiary Viromed Medical GmbH. With a broad customer base in the DACH region and beyond, Viromed aims to further advance the use of cold plasma technology in medicine and realize its growth potential.
The new distribution partnerships are a testament to Viromed's commitment to international growth and its ability to forge strategic alliances. As the company continues to expand its reach, it is well-positioned to become a leading player in the cold plasma medical device market.
